Targeting Neuroblastoma Stem Cells with Retinoic Acid and Proteasome Inhibitor

Comparison of the Side Populations in Pretreatment and Postrelapse Neuroblastoma Cell Lines

(2014) Thomas C. Newton et al.   Translational Oncology

The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma

(2012) Grit Hutter et al.   ANNALS OF HEMATOLOGY

Induction ofNANOGexpression by targeting promoter sequence with small activating RNA antagonizes retinoic acid-induced differentiation

(2012) Xiaoling Wang et al.   BIOCHEMICAL JOURNAL

Intestinal Tumorigenesis Initiated by Dedifferentiation and Acquisition of Stem-Cell-like Properties

(2012) Sarah Schwitalla et al.   CELL

Bortezomib Sensitizes Human Acute Myeloid Leukemia Cells to All-Trans-Retinoic Acid-Induced Differentiation by Modifying the RAR /STAT1 Axis

(2012) M. Ying et al.   MOLECULAR CANCER THERAPEUTICS

Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation

(2012) S M Kumar et al.   ONCOGENE

IRF1 and NF-kB Restore MHC Class I-Restricted Tumor Antigen Processing and Presentation to Cytotoxic T Cells in Aggressive Neuroblastoma

(2012) Silvia Lorenzi et al.   PLoS One

Quantitative proteomic analysis to decipher the differential apoptotic response of bortezomib-treated APL cells before and after retinoic acid differentiation reveals involvement of protein toxicity mechanisms

(2012) Sandrine Uttenweiler-Joseph et al.   PROTEOMICS

Bortezomib Stabilizes Mitotic Cyclins and Prevents Cell Cycle Progression via Inhibition of UBE2C in Colorectal Carcinoma

(2011) Prashant Bavi et al.   AMERICAN JOURNAL OF PATHOLOGY

Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project

(2011) Wendy B. London et al.   JOURNAL OF CLINICAL ONCOLOGY

Hypoxia Selects Bortezomib-Resistant Stem Cells of Chronic Myeloid Leukemia

(2011) Michele Tanturli et al.   PLoS One

The Proteasome Inhibitor Bortezomib Enhances ATRA-Induced Differentiation of Neuroblastoma Cells via the JNK Mitogen-Activated Protein Kinase Pathway

(2011) Peihua Luo et al.   PLoS One

Molecular Mechanisms of Bortezomib Resistant Adenocarcinoma Cells

(2011) Erika Suzuki et al.   PLoS One

The Anti-apoptotic Protein BCL2L1/Bcl-xL Is Neutralized by Pro-apoptotic PMAIP1/Noxa in Neuroblastoma, Thereby Determining Bortezomib Sensitivity Independent of Prosurvival MCL1 Expression

(2010) Judith Hagenbuchner et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Inhibition of all-Trans-retinoic acid-induced proteasome activation potentiates the differentiating effect of retinoid in acute myeloid leukemia cells

(2010) Yanfen Fang et al.   MOLECULAR CARCINOGENESIS

The Combined Therapeutic Effects of Bortezomib and Fenretinide on Neuroblastoma Cells Involve Endoplasmic Reticulum Stress Response

(2009) G. Pagnan et al.   CLINICAL CANCER RESEARCH

The transcriptional foundation of pluripotency

(2009) I. Chambers et al.   DEVELOPMENT

Poor Survival for Infants WithMYCN-Amplified Metastatic Neuroblastoma Despite Intensified Treatment: The International Society of Paediatric Oncology European Neuroblastoma Experience

(2009) Adela Canete et al.   JOURNAL OF CLINICAL ONCOLOGY

Neuroblastoma Cell Lines Contain Pluripotent Tumor Initiating Cells That Are Susceptible to a Targeted Oncolytic Virus

(2009) Yonatan Y. Mahller et al.   PLoS One

Discovery of Novel Proteasome Inhibitors Using a High-Content Cell-Based Screening System

(2009) Irena Lavelin et al.   PLoS One

Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade

(2008) R. Z. Orlowski et al.   CLINICAL CANCER RESEARCH

Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity

(2008) Valérie Combaret et al.   Molecular Cancer